TipRanks Revamps Powerful Stock Screener

Looking for fresh investing inspiration? We have the perfect tool for you. TipRanks has now revamped its powerful stock screener to enable users to take advantage of our unique and valuable stock insights. The new screener is designed to give you flexibility and accuracy in your stock search. Easily discover premium stock ideas specifically matched to your investing requirements by utilizing the screener’s advanced capabilities. Go to screener now<<

Let’s take a closer look at what this entails here:

Find top stock ideas

The upgraded screener includes many exciting new datasets enabling you to refine your search options and find high-quality investing inspiration more easily and efficiently than ever before. New filters include Analyst Price Target and Best Analyst Price Target. The Analyst Price Target specifically is an extremely useful filter that lets you find the stocks with big growth potential according to the Street. Using this filter, you can limit the results to only ‘Strong Buy’ stocks with over 20% upside potential from the current share price to the average analyst price target.

Customize your screener

You can simplify the results by ensuring that the display table reveals only the columns that interest you. See below how you can select the data. You may only be interested in including the column on the Best Analyst Consensus for example or the latest News Sentiment and Media Buzz. The upshot is that by designing the results display to fit your requirements, it is much simpler and easier to pinpoint the best stock ideas for your portfolio.

Order the results to fit your strategy

Once you have set the filters and columns as above- you have a third potential option to further personalize the results. By clicking on the column heading you can order the results by that subject. If- for example- you are most interested in finding the stocks with the highest upside potential you can click on the ‘Analyst Price Target’ heading. This then displays the results starting with the stocks with the highest upside potential first.

In this case that’s biotech Synergy Pharmaceuticals (NASDAQ:SGYP) which has a whopping 385% upside from the current share price to the $8.25 price target. If you click on the heading again, it reverses the stock order i.e. so starting with the lowest upside potential.

Keep your finger on the pulse

As well as the data discussed above, the screener includes a nifty overview of the latest news on each stock. At a glance you can discover the latest stock analysis and events. Simply click on the hyperlinked article to read the full piece. In this way the process of pinpointing top stocks and researching their current position is simplified to just a couple of clicks. Turning to SGYP, we can immediately see by rolling over the ‘article’ logo that the company is due to report new data at Digestive Disease Week- a useful insight given that this event could potentially represent a big catalyst for prices.

Delve deeper into a specific stock

If you click on the stock ticker you can discover further insights on any of the stocks pulled up by the screener. The link takes you to the stock profile page where you have the full range of stock insights. Here you can can see how individual market experts are rating the stock- from analysts to insiders to hedge fund managers.

Clicking on the SGYP ticker reveals that five-star Canaccord Genuity analyst John Newman has just reiterated his Buy rating. This comes with an extremely bullish $13 price target. Newman sees big potential for SGYP’s drug Trulance for abdominal pain: “We maintain our BUY rating and $13 price target based on continued growth in unique Trulance prescribers and our expectation of its long-term success, since it is simpler for physicians and patients to use with a better safety profile than Linzess.”

Discover Your Own Top Stock Ideas With The Stock Screener Now<<

Leave a Reply

Your email address will not be published. Required fields are marked *

Leave a Reply

Your email address will not be published. Required fields are marked *